Compare CNTN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTN | HUMA |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 165.7M |
| IPO Year | 2021 | 2020 |
| Metric | CNTN | HUMA |
|---|---|---|
| Price | $2.04 | $0.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.63 |
| AVG Volume (30 Days) | 810.6K | ★ 4.4M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.10 | 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | N/A | $518.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.39 |
| 52 Week High | $5.27 | $1.90 |
| Indicator | CNTN | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 19.61 |
| Support Level | $2.04 | N/A |
| Resistance Level | $2.40 | $0.75 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 5.06 | 3.53 |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.